We will work closely with you to determine the best course of action
Retatrutide Research Compound 20mg Vial product details Retatrutide Research Compound 20mg Vial product-information listing 20mg research-use-only vial format Product image, pack details, price, and support information shown before enquiry This listing is provided for product-information review Online checkout is not enabled for this listing Supplied strictly for laboratory research use only
Tirzepatide While Semaglutide targets one key hormone (GLP-1), Tirzepatide is a dual-agonist, targeting both GLP-1 and GIP
Heres what the clinical data shows: Most Common: Nausea (affecting 15-44% of users), diarrhea (10-30%), vomiting (7-25%), and constipation (6-24%) Severity: 98.1% of gastrointestinal side effects are mild or moderate, with 99.5% being non-serious Duration: Median duration is 8 days for nausea, 3 days for diarrhea, and 2 days for vomiting Timing: Most side effects occur during initial weeks and dose escalation, declining over time Discontinuation: Only 4.3-10% of users discontinue therapy due to side effects Serious Events: Rare, with no increased risk of pancreatitis or malignancy in clinical trials Management: Slow dose titration, dietary modifications, and hydration significantly reduce symptoms Important Note: Weight loss is NOT caused by side effects
